Post by Jack Shuang Hou

🧬📈 uniQure #Wins FDA #Reversal for #Huntington’s #Gene #Therapy, Shares #Surge 80% as #Filing #Path #Reopens uniQure received a major regulatory boost after the FDA reversed its earlier position and agreed that existing Phase 1/2 data may support an accelerated approval filing for AMT-130 in Huntington’s disease. The decision sent uniQure shares up nearly 80% in premarket trading and could signal a more flexible regulatory approach toward rare disease therapies. 1️⃣ FDA Clears Accelerated Approval Path 📌 AMT-130 is a one-time gene therapy designed to slow progression of Huntington’s disease. 📌 Earlier this year, the FDA said additional trial data would be required before filing. 📌 Following a new meeting, the agency agreed that 3-year Phase 1/2 data may serve as the primary basis for an accelerated approval submission. 📌 uniQure now plans to file in Q3 2026. 2️⃣ Potential Shift in Rare Disease Regulation ⚖️ Investors viewed the decision as an important regulatory signal. Several rare disease and gene therapy companies, including REGENXBIO and Rezolute, Inc., also saw positive share price reactions following the news. Analysts suggested the decision may reflect increasing FDA willingness to consider alternative evidence packages in diseases where traditional large-scale trials are difficult. 3️⃣ Full Approval Path Still Under Discussion 🏥 While the accelerated approval pathway is now open, uniQure continues working with the FDA on confirmatory trial requirements. The company is seeking alignment on using a standard-of-care concurrent control arm rather than the previously requested sham-procedure design. 👥 Leadership Perspective 👨‍💼 uniQure stated that it plans to submit the accelerated approval application in Q3 2026 and remains committed to initiating the confirmatory study without delay. 🧩 My takeaway This is one of the most significant regulatory reversals in the gene therapy sector this year. Beyond AMT-130, investors are paying close attention to whether this reflects a broader shift toward greater regulatory flexibility for rare disease programs with strong long-term data but limited patient populations. 📌 Bottom line: FDA’s reversal gives uniQure a viable accelerated approval pathway for AMT-130, creating a potential first-in-class opportunity in Huntington’s disease and reigniting investor optimism across the gene therapy sector. #uniQure #AMT130 #HuntingtonsDisease #GeneTherapy #FDA #Biotech #RareDisease #CellAndGeneTherapy #AcceleratedApproval #ClinicalTrials #Neuroscience #GeneticMedicine #HealthcareInnovation #LifeSciences #Biopharma #DrugDevelopment #PrecisionMedicine #RegulatoryAffairs #Biotechnology #HealthcareInvesting https://lnkd.in/gjxGADaW